InvestLog
APRE Aprea Therapeutics, Inc. logo

APRE Aprea Therapeutics, Inc.

Healthcare
$0.95+2.15%ClosedMarket Cap: $6.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.17

P/S

52.24

EV/EBITDA

3.21

DCF Value

$2.13

FCF Yield

-198.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

-1523.6%

Operating Margin

-10649.9%

Net Margin

-10121.7%

ROE

-59.5%

ROA

-24.8%

ROIC

-29.4%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-3.3M$—
Q4 null$0.00$-2.5M$—
FY null$0.00$-12.6M$—
Q3 null$0.00$-3.0M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
WedbushOutperform
2026-05-14
HC Wainwright & Co.Buy
2026-03-31
WedbushOutperform
2026-03-31
WedbushOutperform
2026-02-10
HC Wainwright & Co.Buy
2026-01-29

Trading Activity

Insider Trades

View All
Peters Richarddirector
BuyWed Apr 01
Hamill John P.officer: SrVP/CFO/Prin Fin & Acct Ofcr
BuyWed Apr 01
Hamill John P.officer: SrVP/CFO/Prin Fin & Acct Ofcr
SellMon Mar 16
Hamill John P.officer: SrVP/CFO/Prin Fin & Acct Ofcr
SellMon Mar 16
Gilad Orendirector, officer: President/CEO
SellMon Mar 16

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

1.48

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Peers

ACXP logoACXPADIL logoADILAPVO logoAPVOBCDA logoBCDACELZ logoCELZGLTO logoGLTOHCWB logoHCWBINAB logoINABKPRX logoKPRXRNAZ logoRNAZ